Evidence to date: talazoparib in the treatment of breast cancer

Exman, P; Barroso-Sousa, R; Tolaney, SM

Tolaney, SM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Breast Oncol Program, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA.

ONCOTARGETS AND THERAPY, 2019; 12 (): 5177

Abstract

Approximately 5-10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-dam......

Full Text Link